Newsletter Subject

FDA Panel Endorses DFMO for Kids' High-Risk Neuroblastoma in Remission

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Wed, Oct 4, 2023 10:51 PM

Email Preheader Text

Daily Headlines Wednesday, October 04, 2023 Today's Top Stories for {NAME} THE BREAK ROOM CME SPOTLI

[MEDPAGE TODAY]( Daily Headlines Wednesday, October 04, 2023 Today's Top Stories for {NAME} [ONCOLOGY/HEMATOLOGY]( [FDA Panel Endorses DFMO for Kids' High-Risk Neuroblastoma in Remission]( [INFECTIOUS DISEASE]( [How Bad Will This Respiratory Virus Season Be? CDC Weighs In.]( [PSYCHIATRY]( [Esketamine Tops Quetiapine in Treatment-Resistant Depression]( THE BREAK ROOM [Wordectomy: Guess Today’s Medical Condition]( CME SPOTLIGHT [Evidence-Based Management of Adverse Effects of Immunotherapy in Relapsed/Refractory Multiple Myeloma]( [SPECIAL REPORTS]( [Parkinsonism Case Tied to Welding, Improved With Chelation]( [RHEUMATOLOGY]( [Everything (Maybe) You Wanted to Know About Sarilumab for PMR]( THE BREAK ROOM [Play Today’s Wordosis]( ADVERTISEMENT [INFECTIOUS DISEASE]( [Here's How the Novavax COVID Shot Held Up Against Omicron]( CME SPOTLIGHT [Navigating PNH Recognition, Diagnosis, and Treatment]( [MEETING COVERAGE]( [Use of Recent Diagnostic CT Scans for Palliative RT Planning Reduced Treatment Time]( [ALLERGY & IMMUNOLOGY]( [Pediatric EDs Able to Sway Some Families, Clinicians on Penicillin Challenge]( [ONCOLOGY/HEMATOLOGY]( [Drugmaker Plans to Pull Lung Cancer Therapy From the Market]( CME SPOTLIGHT [Evaluating the Cause of Anemia: Diagnosis and Management of Myelodysplastic Syndromes]( [THE BREAK ROOM]( [Spell Check-Up: Is Your Spelling Up to Snuff?]( [SPECIAL REPORTS]( [Coast to Coast, Kaiser Permanente Workers Start 3-Day Strike]( [CARDIOLOGY]( [Aspirin Outcomes No Different With Safety Coating]( CME SPOTLIGHT [Navigating the Rapidly Evolving DLBCL Treatment Landscape to Deliver Quality Care]( [ONCOLOGY/HEMATOLOGY]( [FDA Staff Highly Skeptical of Confirmatory Data on KRAS Inhibitor in NSCLC]( [PSYCHIATRY]( [ADHD and Car Crashes; New Guidance on Stimulant Use Disorder Tx; KarXT Heads to FDA]( [MEETING COVERAGE]( [Hypofractionated RT for Breast Cancer Post-Mastectomy as Effective as Standard RT]( CME SPOTLIGHT [Hitting the Mark? Targeted Antibody-Based Therapy for Diffuse Large B-Cell Lymphoma]( [NEUROLOGY]( [COVID Vaccine, Infection May Affect Migraine Course Slightly]( [SURGERY]( [In BRCA Breast Cancer, Prophylactic Salpingo-Oophorectomy Tied to Better Survival]( [OPINION]( ['Tis the Season of Flea-Borne Typhus]( [ASCO READING ROOM]( [Ovarian Cancer: Best Practices for Managing PARP Inhibitor Side Effects]( [ASCO READING ROOM]( [Ovarian Cancer: Review Goes Deep Into Databases to Better Understand PARPi AEs]( [OPINION]( [Treating Systemic 'Moral Injury' in Medicine]( [MEDICAL JOURNEYS]( [Viral Load: HIV's Most Important Disease Marker]( [MEDICAL JOURNEYS]( [For Your Patients: What 'U=U' Means for You ... and Your Partner]( # Weekly Survey [Trouble Getting the Booster?]( [Slow insurance approvals and supply chain issues]( have resulted in canceled appointments and frustration for patients seeking a COVID-19 booster shot[VOTE >]( Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. [SEE ALL STORIES >]( Got a news tip? MedPage Today offers several ways to provide information to our journalists securely and confidentially. [LEARN MORE >]( [EVERYDAY HEALTH]( © 2023 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Daily_DHE?xid=nl_mpt_DHE_2023-10-04&eun=g1020308d0r) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011

Marketing emails from medpagetoday.com

View More
Sent On

23/06/2024

Sent On

23/06/2024

Sent On

22/06/2024

Sent On

21/06/2024

Sent On

21/06/2024

Sent On

21/06/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.